Indegene Ltd

Indegene Ltd, a healthcare services company, has seen its investment rating upgraded from Hold to Buy, reflecting significant improvements across financial performance, technical indicators, and valuation metrics. The upgrade, effective from 4 August 2026, is underpinned by robust quarterly results, positive financial trends, and bullish technical signals, despite a shift to a more expensive valuation grade.

Indegene Ltd has witnessed a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underpinned by a series of positive signals across key technical indicators, reflecting improving investor sentiment and robust price action in the healthcare services sector.

Indegene Ltd, a notable player in the healthcare services sector, has experienced a significant shift in its valuation parameters, prompting a downgrade in its mojo grade from Buy to Hold. With its price-to-earnings (P/E) ratio rising to 29.78 and price-to-book value (P/BV) climbing to 3.95, the stock now trades at a premium compared to its historical averages and many peers, signalling a more cautious stance for investors.

Indegene Limited, a healthcare services provider with a market capitalisation of ₹12,806.89 crores, reported a flat net profit of ₹116.20 crores for Q1 FY27, virtually unchanged from ₹116.40 crores in the same quarter last year, representing a marginal decline of 0.17%. Despite robust revenue growth of 39.73% year-on-year, the company's profitability failed to keep pace, raising questions about operational efficiency and cost management. The stock traded at ₹531.60 on July 31, 2026, up 3.32% on the day, though it remains down 10.88% from its 52-week high of ₹596.50.

Indegene Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 29 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 July 2026, providing investors with the latest insights into its performance and outlook.

Indegene Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 29 June 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 17 July 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Indegene Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 29 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Indegene Ltd, a small-cap player in the Healthcare Services sector, has recently experienced a subtle shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a 2.36% decline in the latest trading session, the stock’s technical indicators reveal a nuanced picture of price action and trend dynamics that investors should carefully consider amid broader market fluctuations.

Indegene Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish to a bullish stance as of late June 2026. Despite a recent downgrade from a Buy to a Hold rating by MarketsMOJO, the stock’s technical indicators suggest improving price strength and positive momentum, warranting close attention from investors in the healthcare services sector.

Indegene Ltd, a small-cap player in the Healthcare Services sector, has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a modest day decline of 1.45%, the stock’s technical indicators reveal a complex interplay of signals that investors should carefully analyse amid broader market trends.

Indegene Ltd, a small-cap player in the Healthcare Services sector, has seen its investment rating upgraded from Hold to Buy as of 24 June 2026. This change reflects a notable improvement in the company’s technical indicators alongside steady fundamental metrics, despite some recent financial headwinds. The upgrade is driven by a comprehensive reassessment across four key parameters: Quality, Valuation, Financial Trend, and Technicals.

Indegene Ltd has exhibited a notable shift in its technical momentum, transitioning from a sideways trend to a bullish stance, supported by a confluence of positive signals across key indicators such as MACD, moving averages, and the KST oscillator. Despite a modest day decline of 0.61%, the stock’s technical profile and recent upgrades suggest a strengthening outlook within the healthcare services sector.

The 50-day moving average has crossed above the 200-day moving average for Indegene Ltd, signalling a golden cross on 24 Jun 2026. Yet, the stock declined 0.61% on the day this technical event occurred, and monthly indicators remain ambiguous. This juxtaposition of signals calls for a detailed examination of the broader technical and fundamental context.

Indegene Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 08 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Indegene Ltd, a small-cap player in the Healthcare Services sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a modest day gain of 0.66% to close at ₹511.20, the stock’s technical indicators present a complex picture, reflecting mixed signals that investors should carefully analyse amid broader market dynamics.

Indegene Ltd, a small-cap player in the Healthcare Services sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Recent technical indicators reveal a complex picture with mixed signals from MACD, RSI, Bollinger Bands, and moving averages, reflecting cautious investor sentiment amid price declines.